Back to top

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$350.73 USD


-7.49 (-2.09%)

Updated Jun 30, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.75%
5Strong Sell2.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (161 out of 250)

Industry: Medical - Instruments

Trades from $1

Zacks News

Are Options Traders Betting on a Big Move in IDEXX Laboratories (IDXX) Stock?

Investors need to pay close attention to IDEXX Laboratories (IDXX) stock based on the movements in the options market lately.

Steris (STE) Up 1.5% Since Last Earnings Report: Can It Continue?

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Idexx (IDXX) Up 0.3% Since Last Earnings Report?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IDEXX's (IDXX) Soft LPD Sales, Margin Pressure Concern

Distributor purchasing dynamics have an impact on IDEXX's (IDXX) CAG segment product sales.

IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down

Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.

Idexx Laboratories (IDXX) Q1 Earnings Beat Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 0.89% and 0.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA

MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.

Earnings Preview: Idexx Laboratories (IDXX) Q1 Earnings Expected to Decline

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDEXX (IDXX) to Report Q1 Earnings: What's in the Cards?

Strength in CAG Diagnostics and Water businesses is likely to have contributed to IDEXX's (IDXX) top line in the first quarter.

IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists

IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain

Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.

3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Masimo (MASI) Reports Preliminary Q1 Results, Reiterates '22 View

Masimo's (MASI) first-quarter 2022 results are likely to have been dampened by supply chain headwinds.

LHC Group's (LHCG) Deal With Optum to Boost Value-Based Care

LHC Group's (LHCG) deal with Optum is likely to enhance and extend value-based care to patients' homes.

Here's Why You Should Retain Nevro (NVRO) Stock For Now

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Veeva Systems (VEEV) Sees Wider Adoption of Its Development Cloud

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Reasons to Retain Ecolab (ECL) Stock in Your Portfolio For Now

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

Henry Schein (HSIC) Digital Dentistry Gains, Expands Globally

Henry Schein (HSIC) witnesses strength in dental consumable merchandise sales in France, Germany, Austria, Belgium.

Here's Why You Should Invest in IDEXX (IDXX) Stock for Now

Investors are optimistic about IDEXX's (IDXX) strong international performances and favorable 2022 outlook.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.

Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?

Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.

National Vision (EYE) Hurt by Rising Costs, Vendor Dependency

High dependence on a limited number of suppliers exposes National Vision (EYE) to supplier concentration risk.